Restricted
Use only for patients who have documented P. vivax, P. ovale or P. malariae malaria or who have traveled to an area with chloroquine-susceptible P. falciparum malaria.
Chronic use requires color vision and visual field monitoring every 12 months
Tablet: 200mg (= 155mg hydroxychloroquine base)